Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. / Persson, Frederik; Theilade, Simone; Eugen-Olsen, Jesper; Rossing, Peter; Parving, Hans-Henrik.

In: Journal of Diabetes and its Complications, Vol. 30, No. 8, 2016, p. 1440-1442.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Persson, F, Theilade, S, Eugen-Olsen, J, Rossing, P & Parving, H-H 2016, 'Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes', Journal of Diabetes and its Complications, vol. 30, no. 8, pp. 1440-1442. https://doi.org/10.1016/j.jdiacomp.2016.07.003

APA

Persson, F., Theilade, S., Eugen-Olsen, J., Rossing, P., & Parving, H-H. (2016). Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. Journal of Diabetes and its Complications, 30(8), 1440-1442. https://doi.org/10.1016/j.jdiacomp.2016.07.003

Vancouver

Persson F, Theilade S, Eugen-Olsen J, Rossing P, Parving H-H. Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. Journal of Diabetes and its Complications. 2016;30(8):1440-1442. https://doi.org/10.1016/j.jdiacomp.2016.07.003

Author

Persson, Frederik ; Theilade, Simone ; Eugen-Olsen, Jesper ; Rossing, Peter ; Parving, Hans-Henrik. / Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes. In: Journal of Diabetes and its Complications. 2016 ; Vol. 30, No. 8. pp. 1440-1442.

Bibtex

@article{1133f7e27e88432baa078dacf519733b,
title = "Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes",
abstract = "Soluble urokinase plasminogen activator receptor (suPAR) is associated with faster decline in kidney function and the pathogenesis of diabetic nephropathy. However, little is known about the impact of treatment on plasma and urinary levels of suPAR. We aimed to investigate the impact of renin angiotensin system (RAS) single and dual blockade on suPAR levels in patients with type 2 diabetes and albuminuria. We conducted a post-hoc analysis of a randomized controlled crossover trial. Urine and plasma samples were analyzed for suPAR levels. The placebo period was considered reference and all treatment periods were compared to placebo. Patients (n = 22) were treated for 2-month periods with either placebo, irbesartan 300 mg once daily, aliskiren 300 mg once daily or irbesartan/aliskiren combination in random order. Placebo geometric mean plasma (SEM) levels of suPAR were 3.3 ng/mL (1.1) and urine levels were 4.0 ng/mL (1.1). None of the treatments had significant effects on plasma levels of suPAR compared to placebo. Compared to placebo, irbesartan and combination treatment decreased urinary levels of suPAR significantly (-1.3 ng/mL), while aliskiren did not. In patients with type 2 diabetes urinary levels of suPAR were reduced during RAS blockade treatment, which may contribute to renoprotection.",
keywords = "Journal Article",
author = "Frederik Persson and Simone Theilade and Jesper Eugen-Olsen and Peter Rossing and Hans-Henrik Parving",
note = "Copyright {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
doi = "10.1016/j.jdiacomp.2016.07.003",
language = "English",
volume = "30",
pages = "1440--1442",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier",
number = "8",

}

RIS

TY - JOUR

T1 - Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes

AU - Persson, Frederik

AU - Theilade, Simone

AU - Eugen-Olsen, Jesper

AU - Rossing, Peter

AU - Parving, Hans-Henrik

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016

Y1 - 2016

N2 - Soluble urokinase plasminogen activator receptor (suPAR) is associated with faster decline in kidney function and the pathogenesis of diabetic nephropathy. However, little is known about the impact of treatment on plasma and urinary levels of suPAR. We aimed to investigate the impact of renin angiotensin system (RAS) single and dual blockade on suPAR levels in patients with type 2 diabetes and albuminuria. We conducted a post-hoc analysis of a randomized controlled crossover trial. Urine and plasma samples were analyzed for suPAR levels. The placebo period was considered reference and all treatment periods were compared to placebo. Patients (n = 22) were treated for 2-month periods with either placebo, irbesartan 300 mg once daily, aliskiren 300 mg once daily or irbesartan/aliskiren combination in random order. Placebo geometric mean plasma (SEM) levels of suPAR were 3.3 ng/mL (1.1) and urine levels were 4.0 ng/mL (1.1). None of the treatments had significant effects on plasma levels of suPAR compared to placebo. Compared to placebo, irbesartan and combination treatment decreased urinary levels of suPAR significantly (-1.3 ng/mL), while aliskiren did not. In patients with type 2 diabetes urinary levels of suPAR were reduced during RAS blockade treatment, which may contribute to renoprotection.

AB - Soluble urokinase plasminogen activator receptor (suPAR) is associated with faster decline in kidney function and the pathogenesis of diabetic nephropathy. However, little is known about the impact of treatment on plasma and urinary levels of suPAR. We aimed to investigate the impact of renin angiotensin system (RAS) single and dual blockade on suPAR levels in patients with type 2 diabetes and albuminuria. We conducted a post-hoc analysis of a randomized controlled crossover trial. Urine and plasma samples were analyzed for suPAR levels. The placebo period was considered reference and all treatment periods were compared to placebo. Patients (n = 22) were treated for 2-month periods with either placebo, irbesartan 300 mg once daily, aliskiren 300 mg once daily or irbesartan/aliskiren combination in random order. Placebo geometric mean plasma (SEM) levels of suPAR were 3.3 ng/mL (1.1) and urine levels were 4.0 ng/mL (1.1). None of the treatments had significant effects on plasma levels of suPAR compared to placebo. Compared to placebo, irbesartan and combination treatment decreased urinary levels of suPAR significantly (-1.3 ng/mL), while aliskiren did not. In patients with type 2 diabetes urinary levels of suPAR were reduced during RAS blockade treatment, which may contribute to renoprotection.

KW - Journal Article

U2 - 10.1016/j.jdiacomp.2016.07.003

DO - 10.1016/j.jdiacomp.2016.07.003

M3 - Journal article

C2 - 27475262

VL - 30

SP - 1440

EP - 1442

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 8

ER -

ID: 180401749